More News
16 September 2022
Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies13 September 2022
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence7 September 2022
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche7 September 2022
Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines1 September 2022
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders17 August 2022
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery16 August 2022
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology11 August 2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs10 August 2022
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease8 August 2022
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology5 August 2022
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates5 August 2022
Gilead Sciences to acquire MiroBio5 August 2022
Amgen to acquire Chemocentryx for $4 billion in cashNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports